Business Wire

Airline Passenger Capacity is Projected to Grow at 47% in 2022

8.12.2021 12:00:00 EET | Business Wire | Press release

Share

Global aviation analytics firm Cirium, has released its second annual Airline Insights Review, which reveals an industry in recovery and poised for a projected 47% growth in capacity (the number of seats flown) in 2022. This steep increase indicates capacity could return to 2015 levels by the end of next year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005398/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Airlines are poised for a projected 47% growth in capacity (by seats flown) in 2022, as revealed in Cirium's new Airline Insights Review. (Graphic: Business Wire)

Last year, the pandemic and its consequences wiped out 15 years of global passenger capacity growth—based on the total number of seats flown—in a matter of months, reducing 2020 capacity flown to levels last seen in 2005.

Although recovery was varied in 2021, global capacity is forecasted to return to capacity levels seen in 2006 by the end of the year.

Regions with strong domestic markets showed accelerated recovery this year—in particular, in the US and China. In fact, Chinese domestic flights are up 6% compared to pre-pandemic levels in 2019.

Of all the flights tracked January to October 31 worldwide, 78% were domestic flights. International flights experienced a slow recovery with many restrictions in place until Q4 of 2021, and some restrictions still in place, depending on the routes. Indeed, international flights saw a 6% growth in 2021 compared to the same period in 2020.

“The past year has had its challenges as we continued to face fluctuating cases of COVID-19, new variants—most recently Omicron—and varied vaccination programs per country. There is light at the end of the tunnel as we see international travel corridors reopening. However, we will continue to track this momentum as new variants arise and we hope the invaluable analyses in our Airline Insights Report help to navigate what’s to come,” said Jeremy Bowen, CEO of Cirium.

Cirium predicts a year of acceleration in 2022

“Cirium’s experts have analysed 2021 data and formulated forecasts for 2022 and beyond. Near the end of 2022, global capacity will return to 2015 levels, as we see a steep increase in more seats returning to the skies.

“In Cirium’s Airline Insights Report, we have included Seven Things to Look for in 2022 to enable the industry to gain insight into these forecasts and use them to anticipate market developments and make well-informed decisions,” Bowen added.

As more passengers steadily return to the skies, this will mean worldwide domestic traffic (measured in passenger numbers) is predicted to be back to pre-pandemic levels by the end of 2022. International passenger traffic is likely to reach two-thirds of 2019 levels.

Cirium projections show that the global passenger fleet in service will increase to 20,700 by the end of 2022—only a few hundred less than at the end of 2019—pre-pandemic.

The slow recovery of business travel seen so far will change in 2022, with predictions from the industry that there will be a 36% surge in business travel year-over-year. According to Cirium data, business events being tracked online are already increasing for next year.

Conversions of passenger jets to freighters will continue to increase and in 2022, with a potential total of 160 passenger jets converted to freighters—surpassing previous conversion figures.

Aircraft values and lease rates took an unprecedented hit in the past 12 months, however Cirium suggests that they’ve reached the bottom as the values and lease rates for many aircraft types have stabilized and a few are improving. Some aircraft types remain on watch next year, including the Airbus A350 and the Boeing 787.

Cirium anticipates that airlines will increasingly rely on partnerships to carry passengers into partner home markets in 2022. This will mean a shift in airlines flying secondary markets post-pandemic and instead see them taking advantage of their airline partners to fly passengers to secondary cities.

As more flights return to the skies, it’s no surprise that CO2 emissions will increase next year—the CO2 emissions from flights in 2021 were 40% less than pre-pandemic. However, airlines are returning more fuel-efficient fleets to service and sustainability has become front and center in aviation, with many looking at fuel burn and how to reach net zero 2050 targets.

“Cirium anticipates the return to normalcy will usher in more focus on sustainable travel practices, including younger, more fuel-efficient aircraft, and the ability to more closely measure the impact of airline travel on global greenhouse gas emissions,” said Bowen.

To read the full Cirium Airline Insights Review 2021, including the seven predictions of 2022 – click here.

The 2021 Airline Insights Report is Cirium’s collection of expert analyses covering a wide range of topics surrounding airlines at the core and the aviation industry that encircles them. The report covers:

  • Top routes flown and airports in 2021
  • The current state of the global passenger traffic, capacity and fleet
  • Sustainability initiatives in the airline industry
  • Airline startups and new routes flown in 2021
  • Average airfares in key markets
  • Spotlights on APAC and Latin America

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries:
Rachel Humphries, Cirium at media@cirium.com
Mike Arnot, Julliett Alpha at cirium@juliettalpha.com
Paul Charles/Michael Johnson/Callum McGoldrick, PC Agency at cirium@pc.agency

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye